Le Lézard
Classified in: Business
Subjects: PDT, RLE

NRIA Breaks Ground On $49 Million Luxury Apartment Building In West New York, NJ


WEST NEW YORK, N.J., Nov. 15, 2019 /PRNewswire/ -- NRIA hosted a ceremonial groundbreaking today, marking the start of construction on the first luxury high-rise in West New York, New Jersey's business district called The Station.  U.S. Senator Bob Menendez of New Jersey and West New York Mayor Gabriel Rodriguez were among the dignitaries who participated in the event.

West New York Mayor Gabriel Rodriguez (third from the left), Senator Bob Menendez (fifth from left) and Glenn LaMattina (sixth from the left) of NRIA were joined by stakeholders for the ceremonial ground breaking at The Station today.

The $49 million mixed-use project at 4901 Bergenline Avenue will have 97 one- and two-bedroom apartments averaging 960 square feet.  The units will have open floor plans, oversized windows, luxury appliances, and finishes.   Amenities include a rooftop entertainment deck with grilling kitchen, soft seating and panoramic views of Manhattan and the mountains, a state-of-the-art fitness center, and club room.  The private, subterranean garage will have 80 parking spots, and there will be 25 additional off-site spots for a total of 105.

The 10-story, transit-oriented project is being constructed on the site of a former Duane Reade Pharmacy located directly across the street from the Bergenline Light Rail Station. It will be the tallest building in the heart of West New York's business district, and the only luxury high-rise apartment building there.  The Station will open to residents in 2021.

"The Station will be a gamechanger for West New York," said Glenn LaMattina, SVP for Global Business Development of NRIA. "Since the opening of the Bergenline Station back in 2006, it has been the dream of local leaders to build new apartments close to public transportation, and we're proud to be the first to do a large-scale project like this."

NRIA's $49 million investment in West New York will transform the look and feel of the business district and attract other developers and investors, helping to revitalize the business district. 

NRIA is a vertically-integrated and award-winning real estate investment, management and development firm specializing in luxury townhomes, condominiums, and multifamily developments and acquisitions.  Headquartered in Secaucus, New Jersey,  NRIA is a leading specialist in luxury residential design and development with projects underway in the most dynamic urban centers and resort towns on the East Coast. Since 2010, NRIA has acquired and developed or is in the process of producing more than 100+ projects totaling over 2.30 million [sellable/rentable] square feet valued more than $1.125 billion.  NRIA has more than a half-million square feet in the immediate pipeline. 

SOURCE NRIA


These press releases may also interest you

at 23:00
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

at 22:30
Blue Owl Capital Inc. ("Blue Owl") , a leading alternative asset manager, announced today the hiring of Alicia Gregory as a Managing Director based in Sydney.   Alicia brings over 25 years of investing experience with deep relationships and...

at 22:00
Zetrix Foundation and MY E.G. Services Berhad ("MYEG") signed a Memorandum of Understanding (MoU) with MaiCapital, a licensed virtual asset manager in Hong Kong, to collaborate on the launch of a virtual asset fund or Hong Kong virtual assets...

at 21:38
Grupo Elektra, S.A.B. de C.V. (BMV: ELEKTRA* Latibex: XEKT), Latin America's leading specialty retailer and financial services company, and the largest non-bank provider of...

at 21:30
O2Gold Inc. (NEX: OTGO.H) ("O2Gold" or the "Company") is pleased to announce that it has entered into a share exchange agreement dated March 21, 2024 (the "Agreement") with Quebec Aur Ltd., a private Ontario corporation, (the "Target") and its...

at 21:27
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...



News published on and distributed by: